Therapeutic Area
Indication
Ulcerative Colitis
1
PRECLINICAL
PHASE I
PHASE IIA
Phase II
PHASE IIB
PHASE III
MARKET
Based on the structure of ALTB-168, ALTB-268, a second generation antibody with tetravalent design that leads to improved potency, is under development. In vitro and in vivo studies with ALTB-268 have demonstrated a potentially 10-fold increase in activity of down-regulating late-stage, chronically activated T cells (immune cells that cause inflammation) as compared with ALTB-168.
The company is dedicated to bringing forth ALTB-268 into the clinic, currently in a Phase 2a trial with ulcerative colitis patients. Additional autoimmune indications will be explored based on solid signs of clinical efficacy demonstrated with ALTB-168.